Literature DB >> 7603456

Regulation of distinct cyclic AMP-specific phosphodiesterase (phosphodiesterase type 4) isozymes in human monocytic cells.

M W Verghese1, R T McConnell, J M Lenhard, L Hamacher, S L Jin.   

Abstract

Many functions of the immune and inflammatory responses are inhibited by agents that increase intracellular levels of cAMP. Recent investigations have revealed that cAMP levels in inflammatory cells are regulated by cyclic nucleotide phosphodiesterases (PDEs) belonging to the PDE4 family (cAMP-specific PDEs). At least four different genes are known to encode PDE4 isozymes, which are characterized by their selectivity for cAMP over cGMP and their sensitivity to the antidepressant drug rolipram. The aim of our studies was to investigate whether monocytic cells could regulate PDE4 activity and whether certain PDE4 isozymes were expressed preferentially over others. Our results showed that treatment of peripheral blood monocytes or closely related Mono Mac 6 cells with dibutyryl-cAMP or other cAMP-elevating agents transiently increased rolipram-sensitive PDE4 activity 2-3-fold, without concomitant increases in cGMP-inhibited PDE (PDE3) activity. PDE4 activity was predominantly cytosolic, whereas PDE3 activity was localized to the particulate fraction. Our Northern and Western blot studies with reagents recognizing three distinct PDE4 gene products (PDE4A, PDE4B, and PDE4D) revealed that their expression is transcriptionally regulated in monocytic cells. Although none of the three isozymes was detectable under normal culture conditions, all of these were up-regulated when Mono Mac 6 cells were exposed to dibutyryl-cAMP. Distinct differences were observed in their temporal patterns of expression. Endotoxin lipopolysaccharide, a potent monocyte stimulus, also enhanced PDE4 activity in monocytic cells. These data indicate that monocytic cells may express different PDE4 isozymes, depending on their state of activation or differentiation. These isozymes could thus regulate intracellular cAMP levels at various stages of monocyte activation and could thereby be important in limiting the inflammatory response.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7603456

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  25 in total

Review 1.  Immunomodulation by thalidomide and thalidomide analogues.

Authors:  L G Corral; G Kaplan
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

Review 2.  Phosphodiesterase inhibitors: Lily the Pink's medicinal compound for asthma?

Authors:  G Dent; M A Giembycz
Journal:  Thorax       Date:  1996-06       Impact factor: 9.139

3.  The effect of selective phosphodiesterase 3 and 4 isoenzyme inhibitors and established anti-asthma drugs on inflammatory cell activation.

Authors:  K H Banner; E Moriggi; B Da Ros; G Schioppacassi; C Semeraro; C P Page
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

4.  Action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of cAMP-response-element-binding protein (CREB) and p38 mitogen-activated protein (MAP) kinase in U937 monocytic cells.

Authors:  S J MacKenzie; M D Houslay
Journal:  Biochem J       Date:  2000-04-15       Impact factor: 3.857

Review 5.  Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here?

Authors:  M A Giembycz
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

6.  Characterization of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D gene.

Authors:  G B Bolger; S Erdogan; R E Jones; K Loughney; G Scotland; R Hoffmann; I Wilkinson; C Farrell; M D Houslay
Journal:  Biochem J       Date:  1997-12-01       Impact factor: 3.857

7.  Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses.

Authors:  S-L Catherine Jin; Marco Conti
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

8.  Roflumilast inhibits the release of chemokines and TNF-α from human lung macrophages stimulated with lipopolysaccharide.

Authors:  A Buenestado; S Grassin-Delyle; F Guitard; E Naline; C Faisy; D Israël-Biet; E Sage; J F Bellamy; H Tenor; P Devillier
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

9.  Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B isoforms.

Authors:  M Takahashi; R Terwilliger; C Lane; P S Mezes; M Conti; R S Duman
Journal:  J Neurosci       Date:  1999-01-15       Impact factor: 6.167

Review 10.  Thalidomide analogues as anticancer drugs.

Authors:  Jeanny B Aragon-Ching; Haiqing Li; Erin R Gardner; William D Figg
Journal:  Recent Pat Anticancer Drug Discov       Date:  2007-06       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.